Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.86 USD

103.86
156,105

+0.90 (0.87%)

Updated Aug 8, 2025 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Boston Scientific (BSX) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Boston Scientific (BSX) stood at $102.27, denoting a +0.32% change from the preceding trading day.

Zacks Equity Research

Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Boston Scientific (BSX) closed the most recent trading day at $101.64, moving +1.33% from the previous trading session.

Zacks Equity Research

Abbott (ABT) Q4 Earnings Meet Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Abbott Stock Ahead of Q4 Earnings Results: Smart Buy or Risky Move?

by Urmimala Biswas

Abbott's Diagnostics arm is expected to have been driven by the widespread adoption of its top-tier systems and high testing demand in the fourth quarter.

Zacks Equity Research

BSX Stock Rises on Positive Data Announcement at the AF Symposium

by Zacks Equity Research

Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.

Zacks Equity Research

Boston Scientific (BSX) Increases Yet Falls Behind Market: What Investors Need to Know

by Zacks Equity Research

Boston Scientific (BSX) closed the most recent trading day at $98.66, moving +0.5% from the previous trading session.

Zacks Equity Research

PBH or BSX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBH vs. BSX: Which Stock Is the Better Value Option?

Urmimala Biswas headshot

M&A Synergies Drive BSX: Is it Worth Buying the Stock Now?

by Urmimala Biswas

Boston Scientific's recent acquisitions have added numerous products with immense potential.

Zacks Equity Research

Inspire Medical Stock Falls Despite Solid Preliminary Q4 Revenues

by Zacks Equity Research

INSP's revenue growth in the fourth quarter is likely to have been boosted by increased market penetration in existing centers and expansion into new implanting centers.

Zacks Equity Research

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Boston Scientific (BSX) settling at $94.61, representing a -0.28% change from its previous close.

Zacks Equity Research

RVTY Stock Falls Despite FDA Nod for Automated Testosterone Test

by Zacks Equity Research

Revvity aims to expand the FDA-cleared menu for the EUROIMMUN family of ChLIA automation solutions to serve a wider patient pool.

Zacks Equity Research

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Reasons to Retain The Cooper Companies Stock in Your Portfolio Now

by Zacks Equity Research

COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.

Zacks Equity Research

AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines

by Zacks Equity Research

ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business.

Zacks Equity Research

J&J Pauses Sales of Atrial Fibrillation Device, Stock Down

by Zacks Equity Research

J&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips.

Zacks Equity Research

BSX Stock Rises Following Bolt Medical Acquisition Deal Announcement

by Zacks Equity Research

Boston Scientific inks a new agreement to acquire Bolt Medical, developer of Bolt IVL, for approximately $443 million.

Zacks Equity Research

Here's Why You Should Add Glaukos Stock to Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.

Zacks Equity Research

Here's Why You Should Add Accuray Stock to Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

Compelling Reasons to Retain Acadia Healthcare Stock Now

by Zacks Equity Research

ACHC remains well-poised for growth, attributable to sustained demand for behavioral healthcare services, as well as growth initiatives such as acquisitions, bed additions and joint ventures.

Urmimala Biswas headshot

Abbott Stock Trades at a Discounted P/B Value: To Buy or Not to Buy?

by Urmimala Biswas

ABT gains a key position in point-of-care testing, focusing on Infectious Disease, Cardiometabolic & Informatics, Toxicology and Consumer Diagnostics.

Zacks Equity Research

Boston Scientific Corporation (BSX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

OPKO Health Announces Progress in EBV Vaccine Study, Stock Gains

by Zacks Equity Research

OPK aims to advance a novel vaccine candidate for EBV infection, provide protective immunity to patients and prevent these diseases.

Zacks Equity Research

Boston Scientific (BSX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Boston Scientific (BSX) reachead $91.99 at the closing of the latest trading day, reflecting a +0.77% change compared to its last close.

Zacks Equity Research

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

by Zacks Equity Research

Investors are optimistic about GKOS' strength in its product portfolio amid robust demand and expansion in new markets.